Loading stock data…
Alkermes plc (ALKS)
$46.10-0.78 (-1.66%)
Pre-Market$46.33+0.23 (+0.50%)· Last close Sep 4
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alkermes plc in the Healthcare sector is trading at $46.10 with a market capitalization of $8.3B. Wall Street consensus targets $56.00 (17 analysts), implying a +21.5% move over the next 12 months. The stock is currently 17% below its 52-week high of $55.67, remaining 22.2% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $392.91M↑ | $384.55M↓ | $394.19M↑ | $390.66M |
| Gross Profit | — | $331.33M↓ | $338.34M↓ | $342.59M↑ | $341.20M |
| Operating Income | — | -$48.28M↓ | $58.10M↓ | $89.08M↓ | $92.98M |
| Net Income | — | -$66.48M↓ | $49.34M↓ | $82.76M↓ | $87.10M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
130.55
Beta
Defensive asset. Lower volatility than the S&P 500.
0.27
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.75%
Volume
Today's trading volume
1.06M
Recent News
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
The insider still has significant holdings in the company, signaling confidence.
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.